Reviva announces last patient evaluated in pivotal phase 3 recover trial for brilaroxazine in schizophrenia

Cupertino, calif., sept. 25, 2023 (globe newswire) -- reviva pharmaceuticals holdings, inc. (nasdaq: rvph) (“reviva” or the “company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (cns), inflammatory and cardiometabolic diseases, today announced that the last patient in its global pivotal phase 3 recover study evaluating brilaroxazine for schizophrenia has now completed the study.
RVPH Ratings Summary
RVPH Quant Ranking